As we head into summer, many of us are taking stock of habits we resolved to change at the start of the year. Perhaps we are trying to eat better, start a new exercise regime, get to bed earlier, or quit smoking.
Despite our resolve, we have a hard time sticking to the program. In this letter we are going to address what makes us have such a hard time changing our habits, and how we might be able to improve.
Click here to read the full article…

One in nine women in the United States experience symptoms of postpartum depression, a terrifying illness that is often difficult to treat.
That’s why we’re excited by news that the FDA has approved Brexanolone, a drug over 40 years in the making that is the first ever to specifically target the condition. The approval of Brexanolone is a cause for celebration for the entire field of neuroscience. Click here to read the full article…

We are proud to announce that Hope for Depression Research (HDRF) founder and Chair Audrey Gruss recently was honored at the 2019 Women of Distinction luncheon by Palm Beach Atlantic (PBA) University in Florida.
Click here to read the full article…

A new antidepressant is expected to soon be approved by the Food and Drug Administration.
The New York Times reported yesterday that an advisory panel at the agency has voted in favor of recommending approval of the new drug, the nasal spray Esketamine, to treat severely depressed patients.
Click here to read the full article…

Seated Left to Right: Jeff Lima, Kelly Lennon-Martucci, Louisa Benton, and Hope Kronman
Standing: Daniel Lampert and Aidan Golub, Student Organizers
Hope for Depression Research Foundation was proud to conduct an expert panel on “Bullying and Mental Health” at the Open Minds summit held January 10 at the Solomon Schechter High School in Westchester, NY.
Click here to read the full article…